Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

CONTEXT: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin. OBJECTIVE: To demonstrate the superiority of semag...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodbard, Helena W, Lingvay, Ildiko, Reed, John, de la Rosa, Raymond, Rose, Ludger, Sugimoto, Danny, Araki, Eiichi, Chu, Pei-Ling, Wijayasinghe, Nelun, Norwood, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2018
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991220/
https://www.ncbi.nlm.nih.gov/pubmed/29688502
http://dx.doi.org/10.1210/jc.2018-00070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991220/
https://www.ncbi.nlm.nih.gov/pubmed/29688502
http://dx.doi.org/10.1210/jc.2018-00070

Ejemplares similares